Viktoria Rungelrath, Mushtaq Ahmed, Linda Hicks, Shannon M Miller, Kendal T Ryter, Kyle Montgomery, George Ettenger, Alexander Riffey, Walid M Abdelwahab, Shabaana Abdul Khader, Jay T Evans
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is one of the top infectious killers in the world. The only licensed vaccine against TB, Bacille Calmette-Guérin (BCG), provides variable protection against pulmonary TB, especially in adults. Hence, novel TB vaccine approaches are urgently needed. Both Th1 and Th17 responses are necessary for protection against TB, yet effective adjuvants and vaccine delivery systems for inducing robust Th1 and Th17 immunity are lacking. Herein we describe a synthetic Mincle agonist, UM-1098, and a silica nanoparticle delivery system that drives Th1/Th17 responses to Mtb antigens...
June 6, 2024: NPJ Vaccines